SYRE: Spyre Therapeutics, Inc. Stock

by  •  • Comments Off on SYRE: Spyre Therapeutics, Inc. Stock

SIC 2834 – Pharmaceutical Preparations

Valuation
Market Cap ($M) 1,315.61
Enterprise Value ($M) 1,399.85
Book Value ($M) 327.39
Book Value / Share 5.58
Price / Book 4.02
NCAV ($M) 327.38
NCAV / Share 5.58
Price / NCAV 4.02

Profitability (mra)
Return on Invested Capital (ROIC) -0.66
Return on Assets (ROA) -0.63
Return on Equity (ROE) -1.17

Liquidity (mrq)
Quick Ratio 7.32
Current Ratio 7.32

Balance Sheet (mrq) ($M)
Current Assets 421.08
Assets 421.09
Liabilities 93.70
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 0.00
Operating Income 0.00
Net Income 0.00
Earnings Per Share Basic And Diluted n/a

Cash Flow Statement (mra) ($M)
Cash From Operations 0.00
Cash from Investing 0.00
Cash from Financing 0.00

(click for more detail)

File Date Form Activist 13D/G Investors Ownership
(%)		 Change
(%)
9 days ago 13G/A Rtw Investments, Lp
9 days ago 13G/A Venrock Healthcare Capital Partners III, L.P.
9 days ago 13G/A Perceptive Advisors Llc
11-14 13G/A Avoro Capital Advisors LLC 1.70 -51.88
11-14 13G/A Commodore Capital Lp 3.90 2.79
11-12 13G/A Fmr Llc 15.00 15.81
11-08 13G BlackRock, Inc. 5.20 0.00
10-23 13G Deutsch Peter E. 6.99
04-25 13D/A Fairmount Funds Management LLC 11.17 439.01
2024-02-14 13G/A Logos Global Management LP 0.40
2024-02-14 13G/A Rock Springs Capital Management LP 0.00
2024-02-14 13G/A Baker Bros. Advisors Lp 0.00
2024-02-14 13G/A EcoR1 Capital, LLC 2.50
2024-02-14 13G/A Nantahala Capital Management, LLC 0.00
2024-02-13 13G/A Affinity Asset Advisors, LLC 1.81
2024-02-13 13G/A Suvretta Capital Management, Llc 1.00
2024-02-13 13G/A BCLS II Equity Opportunities, LP 0.00
2024-02-13 13G/A Polar Capital Holdings Plc 1.05
2024-02-08 13G/A Integrated Core Strategies (us) Llc 0.30

Top 13F Investors Shares
(1000)		 Change
(%)		 Value
($1000)		 Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2024-11-18 10-Q/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q/A (Amendment No. 1)
2024-11-18 10-Q/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q/A (Amendment No. 1)
2024-11-18 10-Q/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q/A (Amendment No. 1)
2024-11-18 10-K/A re UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-K/A (Amendment No. 2)
2024-11-07 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q
2024-08-07 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q
2024-05-09 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q
2024-03-01 10-K/A re UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-K/A (Amendment No. 1)
2024-02-29 10-K re UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-K

(click for more detail)
Short Volume
Market Date Short Volume Total Volume Short Volume Ratio
2025-02-21 166,444 636,333 26.16
2025-02-20 103,264 282,779 36.52
2025-02-19 74,982 208,041 36.04
2025-02-18 136,941 572,626 23.91

(click for more detail)

Similar Companies
STTK – Shattuck Labs, Inc. SVRA – Savara Inc.
SWTX – SpringWorks Therapeutics, Inc. SYRS – Syros Pharmaceuticals, Inc.
TARS – Tarsus Pharmaceuticals, Inc.


Financial data and stock pages provided by
Fintel.io